Epoprostenol Market Size & Growth Analysis to 2030

The global epoprostenol market size is accounted to grow at a significant CAGR of 3% during the forecast period from 2021 to 2027 and expected to reach at USD 2,286.3 million by 2027. The growing incidence of pulmonary arterial hypertension worldwide primarily drives the epoprostenol market growth. Additionally, rising public health awareness and effective implementation of treatment guidelines regarding the treatment of primary pulmonary hypertension will further consolidify the epoprostenol market growth.

Epoprostenol is enzymatically biosynthesized form the prostaglandin endoperoxides in human vascular tissue as a sodium salt. It possesses potent vasodilator effects, it belongs to the family of prostacyclin (PG12) class which activates the G protein coupled receptors and endothelial cells present in the human body, which further activates Cyclic AMP to inhibit platelet aggregation. It is available as an injectable, powder for reconstitution in vials of dose strengths of 0.5mg/vial and 1.5mg/vial. Epoprostenol needs to be taken under medical supervision to prevent the occurrence of drug-related severe adverse events.

Market Drivers:

Pulmonary Arterial Hypertension (PAH): Epoprostenol is primarily used for the treatment of pulmonary arterial hypertension, a chronic and progressive condition characterized by high blood pressure in the arteries of the lungs. The increasing prevalence of PAH and the need for effective treatment options drive the demand for epoprostenol.

Improved Diagnosis and Awareness: With advancements in medical diagnostics and increased awareness about PAH, more cases are being diagnosed at an earlier stage. This leads to an increased demand for treatment options, including epoprostenol, to manage the condition and improve patient outcomes.

Efficacy and Clinical Benefits: Epoprostenol has shown significant clinical benefits in the treatment of PAH, such as improving exercise capacity, reducing symptoms, and enhancing quality of life. The proven efficacy of epoprostenol contributes to its demand as a preferred treatment option for patients with severe PAH.

Orphan Drug Designation and Regulatory Support: Epoprostenol has received orphan drug designation from regulatory authorities in many countries. This designation provides various incentives, including market exclusivity, regulatory assistance, and financial benefits, which incentivize pharmaceutical companies to invest in the development and commercialization of epoprostenol.

Advancements in Drug Delivery Systems: Epoprostenol is typically administered intravenously through continuous infusion pumps. The development of advanced drug delivery systems, such as implantable pumps or portable infusion devices, has made the administration of epoprostenol more convenient and patient-friendly, increasing its adoption.

Research and Development: Ongoing research and development activities focused on improving the formulation, delivery, and effectiveness of epoprostenol can drive market growth. Efforts to develop novel formulations, explore combination therapies, and investigate alternative routes of administration can expand the market for epoprostenol.

Healthcare Policies and Reimbursement: Government healthcare policies, reimbursement frameworks, and insurance coverage for PAH treatments play a role in driving the epoprostenol market. Favorable reimbursement policies and adequate insurance coverage ensure patient access to epoprostenol, contributing to market growth.

Pharmaceutical Industry Collaborations: Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can drive the development and commercialization of epoprostenol. Partnerships aimed at conducting clinical trials, expanding the drug’s indications, or improving its formulation can contribute to market growth.

Market Attributes:

Market Insights:

Primary pulmonary hypertension is representing the largest market share in the clinical application segment for the epoprostenol market. Effective implementation of treatment guidelines pertaining to the treatment of primary pulmonary hypertension and increasing public health awareness regarding the therapeutic efficacy of epoprostenol in its treatment together fortify the market growth. It is further subdivided into heritable pulmonary arterial hypertension (HPAH), idiopathic pulmonary arterial hypertension (IPAH), associated pulmonary arterial hypertension (APAH), etc. It is predicted that during the forecast period that patients suffering from NYHA Functional Class III-IV symptoms will be on a rise, hence clinical trial investigation regarding the therapeutic efficacy and safety of epoprostenol in resolving the symptoms will be progressively conducted.

To know more about the study, request a report sample

Hospital pharmacy is presently leading the distribution channel segment for the epoprostenol market. The dose posology varies as per the category of patients i.e. pediatric and adult, hence precise compounding by hospital pharmacists is mandatory to prevent the occurrence of severe drug-related adverse events. Retail pharmacy is expected to register comfortable market growth in the near future owing to the flourishing generic drugs market in the developing regions and its ability to provide medication at a lower price to patients residing in remote locations.

The epoprostenol comprehensive study offers an in-depth analysis of industry trends, market size, competitive analysis, and market forecast – 2020 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.

The epoprostenol market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

• 2018-19 – Historical Year
• 2020 – Base Year
• 2021-2027 – Forecast Period

Market Segmentation:

By Clinical Application:

• Primary Pulmonary Hypertension
• NYHA Functional Class III-IV Symptoms

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage:

North America is the supreme leader in the geography segment for the epoprostenol market. The growing incidence of primary pulmonary hypertension primarily drives the epoprostenol market growth in the region. As per the latest information provided by the Center for Disease Control and Prevention (CDC), the prevalence rate of primary pulmonary hypertension is 2 cases per million Americans. Additionally, the presence of developed healthcare infrastructure and affordable reimbursement scenarios further propel the market growth in the region. Europe is the second-largest regional segment for the epoprostenol market. Strategic collaboration between academic research institute and pharmaceutical giants in understanding the therapeutic efficacy of epoprostenol in resolving NYHA Functional Class III-IV symptoms in patients consolidates the market growth in the region. The Asia Pacific is anticipated to be the fastest growing regional segment during the forecast period owing to the flourishing generic drugs market and effective implementation of treatment guidelines pertaining to the treatment of pulmonary hypertension in the region.

Market Competition Assessment:

Key players operating in the global epoprostenol market are Actelion (Johnson & Johnson), Merck & Co., Inc., Sandoz, Inc., GlaxoSmithKline, Plc., and Mayne Pharma. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Actelion (Johnson & Johnson)
• Merck & Co., Inc.
• ROTEXMEDICA
• GlaxoSmithKline, Plc.
• Sandoz, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• Gebro Pharma GmbH
• Mayne Pharma
• Campus Pharma AB

Key Questions Answered by Epoprostenol Market Report:

• Global epoprostenol market forecasts from 2021-2027
• Regional epoprostenol market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
• Epoprostenol submarket forecasts from 2021-2027 covering the market by clinical application, by distribution channel, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to epoprostenol market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level epoprostenol markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the epoprostenol market